Mercedes Gironella

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 324 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Laura Rosiñol, Albert Oriol, Rafael Ríos et al. · Blood · 2019 · 216 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Bruno Paiva, María‐Teresa Cedena, Noemí Puig et al. · Blood · 2016 · 150 citations · Full text

Medicine, Hematology, Oncology +17

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Alejandro Medina, Noemí Puig, Juan Flores‐Montero et al. · Blood Cancer Journal · 2020 · 115 citations · Full text

Medicine, Hematology, Hematologic Oncology +13